Efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 4 infection: A pooled analysis.
Asselah TarikHendrik W ReesinkJan GerstoftVictor De LedinghenPaul J PockrosMichael RobertsonPeggy HwangErnest Asante-AppiahJanice WahlBach-Yen NguyenEliav BarrRohit TalwaniLawrence SerfatyPublished in: Liver international : official journal of the International Association for the Study of the Liver (2018)
The regimens of 12 weeks of elbasvir/grazoprevir without ribavirin, and 16 weeks of elbasvir/grazoprevir plus ribavirin, were efficacious in HCV GT4-infected treatment-naïve and treatment-experienced participants respectively. Baseline NS5A resistance-associated substitutions did not impact the efficacy of elbasvir/grazoprevir in GT4-infected participants.